Peer ReviewedOncolines®2025-07-20T22:20:55+02:00

Publications by Oncolines Scientists

van Haaften et al. (2025) Synthesis and absolute configuration of the sesquitertene lactone EPD, a natural product with broad antitumor cell activity via a unique mechanism of action. Journal of Natural Products, online first 4 July 2025. (Together with Symeres and Leiden University Medical Center)

Grobben (2024) Targeting amino acid-metabolizing enzymes for cancer immunotherapy. Frontiers in Immunology, 15:1440269.

Jang et al. (2023) Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor. Cancer Chemotherapy and Pharmacology, 91:491–499. (Collaboration with Elevar Therapeutics)

Grobben et al. (2023) Amino acid-metabolizing enzymes in advanced high-grade serous ovarian cancer patients: value of ascites as biomarker source and role for IL4I1 and IDO1. Cancers, 15(3):893. (Collaboration with Radboud University Medical Center and Pangaea Oncology)

Kooijman et al. (2022) Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 12:953013.

Conlon et al. (2021) Comparative analysis of drug response and gene profiling of the HER2-targeted tyrosine kinase inhibitors. British Journal of Cancer, 124(7):1249–1259. (Collaboration with Dublin City University and Puma Biotechnology, Inc.)

Perez-Pardo et al. (2021) Pharmacological validation of TDO as a target for Parkinson’s disease. The FEBS Journal, 288:4311–4331. (Collaboration with Dublin City University and Puma Biotechnology, Inc.)

Grobben et al. (2021) Targeting indoleamine 2,3-dioxygenase in cancer models using the novel small molecule inhibitor NTRC 3883-0. Frontiers in Immunology, 11:609490. (Collaboration with Radboud University Medical Center)

den Ouden et al. (2020) Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. Oncotarget, 11:4570–4581. (Collaboration with Radboud University Medical Center)

Grobben et al. (2020) High-throughput fluorescence-based activity assay for Arginase-1. SLAS Discovery, 25(9):1018–1025.

Grobben et al. (2020) Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. Journal of Structural Biology: X, 4:100014.

Uitdehaag et al. (2019) Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Molecular Cancer Therapeutics, 18(2):470–481.

Zaman et al. (2017) TTK inhibitors as a targeted therapy for CTNNB1 (β-catenin) mutant cancers. Molecular Cancer Therapeutics, 16(11):2609–2617.

Uitdehaag et al. (2017) Target residence time-guided optimization on TTK kinase results in inhibitors with potent anti-proliferative activity. Journal of Molecular Biology, 429:2211–2230.

Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. Oncotarget, 8(24):38309–38325. (Collaboration with Netherlands Cancer Institute)

Willemsen-Seegers et al. (2017) Compound selectivity and target residence time of kinase inhibitors studied with surface plasmon resonance. Journal of Molecular Biology, 429:574–586.

Uitdehaag et al. (2016) Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, aurora kinase and EZH2 inhibitors. Molecular Cancer Therapeutics, 15 (12):3097–3109.

de Roos JA, Uitdehaag JC, de Man AP, Buijsman RC, Zaman GJR, inventors; Netherlands Translational Research Center B.V., assignee. Prognostic biomarkers for TTK inhibitor chemotherapy. Patent WO 2016/166255 A1. 2016 Oct 20

Uitdehaag et al. (2015) Selective targeting of CTNNB1-, KRAS- or MYC-driven cell growth by combinations of existing drugs. PLoS ONE, 10(5):e0125021.

Seegers et al. (2014) High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes. Journal of Biomolecular Screening, 19(9):1266–1274.

Uitdehaag et al. (2014) Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS ONE, 9(3):e92146.

References by Clients to our Services

Gaudio et al. (2025) Novel flavenoid derivatives show potent efficacy in human lymphoma models. eJHaem 6:e70081. (Affiliations: Floratek, the Institute of Oncology Research Bellinzona, the Jackson Laboratory, and Oncolines)

Carragher et al. (2025) Overcoming Osimertinib resistance in NSCLC with NXP900, a phase 1, highly selective and potent first-in-class total YES1/SRC inhibitor. Poster presentation at AACR Annual Meeting (Affiliations: University of Edinburgh and Nuvectis Pharma Inc.)

Carragher et al. (2025) Overcoming Osimertinib resistance in NSCLC with NXP900, a phase 1, highly selective and potent first-in-class total YES1/SRC inhibitor. Poster presentation at AACR Annual Meeting (Affiliations: University of Edinburgh and Nuvectis Pharma Inc.)

Park et al. (2025) High CRBN expression in neuroendocrine cancer creates a vulnerability to GSPT1 molecular glue degraders: Target identification selection for CYRS1542 development. Poster presentation at AACR Annual Meeting (Affiliation: Cyrus Therapeutics)

Gaudio et al. (2025) Discovery of first in class, polyphenolic inhibitors of CKAP4 and their tumor activity in ovarian and endometrial cancer. Poster presentation at AACR Annual Meeting (Affiliations: Floratek, Symeres, 2Bind, Carcinotech, Pelago, and Oncolines)

van der Veen (2025) Shedding light on a novel PI3K inhibitor: Enabling isoform-specific inhibition to establish clinical success. Oral presentation at Hanson Wade Kinase Targeted Drug Discovery Summit, Boston, February 2025 (Affiliation: IOnctura)

Hollick et al. (2025) Discovery and characterization of DNA polymerase theta inhibitors for the treatment of cancer. Poster presentation at Hanson Wade DDR Inhibitors Summit, Boston, January 2025 (Affiliation: Breakpoint Therapeutics GmbH)

Khameneh et al. (2024) The bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells. Mucosal Immunology, 17:346–358. (Affiliations: IBR Bellinzona, OM Pharma, and Oncolines)

Nishiguchi et al. (2024) Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nature Communications, 15:482. (Affiliation: St. Jude Children’s Hospital)

Perera et al. (2023) Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors. Poster presentation at AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics. (Affiliation: DeuterOncology N.V.)

Gupta et al. (2023) High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models. Poster presentation at AACR Annual Meeting. (Affiliation: Jazz Pharmaceuticals, Inc.)

Gorter et al. (2023) Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab. Poster presentation at AARC Annual Meeting 2023. (Affiliation: Merus N.V.)

King et al. (2022) Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles. Poster presentation at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (Affiliations: University of Edinburgh, Cancer Research U.K., and Nuvectis Pharma Inc.)

Hughes et al. (2022) Uncovering the molecular mechanisms which predict sensitivity to a novel SRC kinase inhibitor NXP900 to inform personalized healthcare strategies. Poster presentation at AACR Annual Meeting 2022. (Affiliations: Cancer Research U.K., University of Edinburgh, and Nuvectis Pharma Inc.)

Lane et al. (2022) BAL0891: a novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity. Poster presentation at ESMO TAT conference 2022. (Affiliation: Basilea Pharmaceutica International Ltd.)

Cordo et al. (2022) Phosophoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 13:1048. (Affiliation: Prinses Máxima Center for Pediatric Oncology)

van der Zwet et al. (2021) MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia, 35 (12):3394-3405. (Affiliation: Prinses Máxima Center for Pediatric Oncology)

Beauchamp et al. (2020) Targeting N-myristoylation for therapy of B-cell lymphomas. Nature Communications, 11:5348. (Affiliations: University of Alberta and Pacylex Pharmaceuticals)

Grünewald et al. (2019) Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. International Journal of Cancer, 145 (5): 346–1357. (Affiliation: Bayer AG)

Gentile et al. (2018) A Novel interaction between the TLR7 and a colchicine derivative revealed through a computational and experimental Study. Pharmaceuticals, 11(1):22. (Affiliation: University of Alberta)

Wentsch et al. (2017) Optimized target residence time: type 1½ inhibitors for p38a MAP kinase with improved binding kinetics through direct interaction with the R-spine. Angewandte Chemie International Edition, 56(19):5363–5367. (Affiliations: University of Tübingen and NTRC)

Bohnacker et al. (2017) Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications, 8:14683. (Affiliation: University of Basel)

Politz et al. (2017) Preclinical activity of the FGFR inhibitor rogaratinib (BAY 1163877) alone or in combination with antihormonal therapy in breast cancer. Cancer Research, 77(13 Supplement):1079. (Affiliation: Bayer AG)

Li et al. (2016) IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLoS Med, 13(12):e1002200. (Affiliations: Erasmus MC and NTRC)